Suppr超能文献

水溶性聚合物对晶体成核和生长的抑制及其对无定形药物过饱和度曲线的影响。

Inhibition of crystal nucleation and growth by water-soluble polymers and its impact on the supersaturation profiles of amorphous drugs.

机构信息

Physical Chemistry, Analytical Research Laboratories, Eisai Product Creation Systems, Eisai Company Ltd., Tsukuba, Ibaraki 300-2635, Japan.

出版信息

J Pharm Sci. 2013 Jul;102(7):2273-81. doi: 10.1002/jps.23588. Epub 2013 May 8.

Abstract

The impact of water-soluble polymers on drug supersaturation behavior was investigated to elucidate the role of water-soluble polymers in enhancing the supersaturation levels of amorphous pharmaceuticals. Hydroxypropyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and Eudragit L-100 (Eudragit) were used as representative polymers, and griseofulvin and danazol were used as model drugs. Supersaturation profiles of amorphous drugs were measured in biorelevant dissolution tests. Crystal growth rate was measured from the decrease in dissolved drug concentration in the presence of seed crystals. Nucleation kinetics was evaluated by measuring the induction time for nucleation. All experiments were performed in the presence and absence of polymers. The degree of supersaturation of the amorphous model drugs increased with an increase in the inhibitory efficiency of polymers against crystal nucleation and growth (HPMC > PVP > Eudragit). In the presence of HPMC, the addition of seed crystals diminished the supersaturation ratio dramatically for griseofulvin and moderately for danazol. The results demonstrated that the polymers contributed to drug supersaturation by inhibiting both nucleation and growth. The effect of the polymers was drug dependent. The detailed characterization of polymers would allow selection of appropriate crystallization inhibitors and a planned quality control strategy for the development of supersaturable formulations.

摘要

研究了水溶性聚合物对药物过饱和行为的影响,以阐明水溶性聚合物在提高无定形药物过饱和度水平方面的作用。羟丙基甲基纤维素(HPMC)、聚乙烯吡咯烷酮(PVP)和尤特奇 L-100(Eudragit)被用作代表性聚合物,灰黄霉素和炔雌醇被用作模型药物。在生物相关的溶解试验中测量了无定形药物的过饱和度曲线。通过测量存在晶种时溶解药物浓度的下降来测量晶体生长速率。通过测量成核诱导时间来评估成核动力学。所有实验均在聚合物存在和不存在的情况下进行。随着聚合物对晶体成核和生长抑制效率的增加,无定形模型药物的过饱和度增加(HPMC > PVP > Eudragit)。在 HPMC 的存在下,添加晶种会显著降低灰黄霉素的过饱和度比,对炔雌醇的影响适中。结果表明,聚合物通过抑制成核和生长来促进药物过饱和。聚合物的作用取决于药物。对聚合物的详细表征将允许选择合适的结晶抑制剂,并制定用于开发过饱和制剂的计划质量控制策略。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验